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There is concern about compounds in the
environment that could partially mimic the
effects of estrogen, which could possibly
explain the rising incidence of reproductive
abnormalities and certain cancers (Miller and
Sharpe 1998). These environmental estrogens
are a structurally very diverse group of com-
pounds that can only be identiﬁed as environ-
mental estrogens by carrying out functional
studies. One compound of concern is bisphe-
nol A (BPA), a monomer component of poly-
carbonate plastics and epoxy resins. Humans
are exposed to BPA when it leaks from plastic
packaging and dental appliances (Feldman
1997), and nanomolar concentrations have
been measured in human serum (Takeuchi
and Tsutsumi 2002). Recently, it was reported
that BPA could cause meiotic aneuploidy
when female mice were exposed unintention-
ally through damaged cage material (Hunt
et al. 2003). BPA has been found to possess
weak estrogenic properties in in vitro assays
with an EC50 (median effective concentration)
about 10,000 times less than strong estrogens
such as 17β-estradiol (E2) and diethylstilbe-
strol (DES) (Kim et al. 2001; Kuiper et al.
1998; Perez et al. 1998). However, the in vivo
estrogenic potential of BPA can vary depend-
ing on animal species or strain studied
(Milligan et al. 1998; Steinmetz et al. 1997,
1998). In addition, the end point is very
important. It was shown that BPA did induce
DNA synthesis in vaginal epithelium of
Fischer 334 rats but did not in Sprague-
Dawley rats, whereas in both strains BPA
increased c-fos mRNA expression (Long et al.
2000). Two classical in vivo assays, the rodent
uterine wet weight assay and the vaginal
cornification assay, have traditionally been
used for testing estrogenic activity of com-
pounds. In these assays, BPA has been found
to be active (Ashby and Tinwell 1998; Markey
et al. 2001; Papaconstantinou et al. 2000) as
well as inactive (Coldham et al. 1997; Gould
et al. 1998; Mehmood et al 2000; Tinwell
et al. 2000). When found active, its potency
was four orders of magnitude lower than that
of DES, confirming the weak estrogenicity
measured in in vitro assays.
It has been proposed that the developing
embryo may be much more susceptible to
harmful effects of environmental estrogens
compared with adult animals (Bigsby et al.
1999; Dencker and Eriksson 1998; McLachlan
2001; Miller 1983). The best-known example
of a developmentally active compound is the
synthetic estrogen DES, which was prescribed
from the 1940s until the 1970s to prevent mis-
carriages. Children exposed to DES in utero
developed abnormalities and cancer of the
reproductive tract, whereas these effects were
not found in their mothers (Herbst et al. 1971;
McLachlan et al. 1975). Structural similarities
between DES and BPA are evident, and it has
been suggested that prenatal exposure to BPA
may cause abnormalities similar to those
elicited by DES (vom Saal et al. 1998).
Experiments examining the estrogenic effects
of BPA on embryos have led to contradictory
ﬁndings. Although some studies have reported
prostate enlargement in offspring of BPA-
exposed mice (Howdeshell et al. 1999), others
reported no effect (Ashby et al. 1999; Cagen
et al. 1999; Nagao et al. 2002; Welshons et al.
1999). Levels of BPA in amniotic fluid at
15–18 weeks of gestation have been shown to
be 5-fold higher than serum levels in both
pregnant and nonpregnant women, suggesting
a possible accumulation of BPA in the early
embryo (Ikezuki et al. 2002), although
Domoradzki et al. (2003) could not conﬁrm
this in animal experiments. Unfortunately,
there is no model in which estrogen effects
can be determined directly in embryos.
We have developed an approach, using
transgenic reporter mice, that allows us to
determine direct activation of estrogen recep-
tor (ER) signaling in embryos. For this, we
used our recently established transgenic mice
model (Lemmen et al. 2004); direct activation
of ERs is detected photometrically by meas-
uring luciferase activity, allowing both quanti-
tative and time-course analysis of estrogen
target gene activation in vivo. Other estrogen
reporter mice that have been generated do not
exclude estrogen-response-element (ERE)–
independent activation because of the presence
of other promoter sequences (Ciana et al.
2001; Nagel et al. 2001; Toda et al. 2004). In
our model, activation of the construct via
promoter sites other than the EREs is avoided
by using only a minimal TATA box in the
construct, resulting in low background activ-
ity. Although in natural promoters ERE
sequences are often found together with other
enhancer sequences and other ways of ER
transactivation (e.g., via AP1 sites) are possi-
ble, we chose a reductionistic approach, with
only ERE sequences in the synthetic pro-
moter used. In the present study, we used this
model to examine the ability of BPA—in
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Environmental estrogens are of particular concern when exposure occurs during embryonic
development. Although there are good models to study estrogenic activity of chemicals in adult ani-
mals, developmental exposure is much more difﬁcult to test. The weak estrogenic activity of the
environmental estrogen bisphenol A (BPA) in embryos is controversial. We have recently generated
transgenic mice that carry a reporter construct with estrogen-responsive elements coupled to
luciferase. We show that, using this in vivo model in combination with the IVIS imaging system,
activation of estrogen receptors (ERs) by maternally applied BPA and other estrogens can be
detected in living embryos in utero. Eight hours after exposure to 1 mg/kg BPA, ER transactivation
could be signiﬁcantly induced in the embryos. This was more potent than would be estimated from
in vitro assays, although its intrinsic activity is still lower than that of diethylstilbestrol and
17β-estradiol dipropionate. On the basis of these results, we conclude that the estrogenic potency
of BPA estimated using in vitro assays might underestimate its estrogenic potential in embryos.
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DES and 17β-estradiol dipropionate (EP)—to
activate endogenous ERs present in mouse
embryos (Lemmen et al. 1999). Surprisingly,
we found BPA to be more potent in activating
embryonic ERs than would be expected on
the basis of its in vitro activity.
Materials and Methods
Transgenic animals. We used transgenic ani-
mals carrying a reporter construct that con-
sists of three estrogen-responsive elements
(GAGCTTAGGTCACTGTGACCT)
upstream of a minimal human E1B TATA pro-
moter sequence (GGGTATATAAT) coupled
to luciferase surrounded by chicken β-globin
insulator (Chung et al. 1993) sequences
(Lemmen et al. 2004). To obtain transgenic
embryos, heterozygote transgenic males from
line INS3 were mated with wild-type females
(F1 from C57Bl/6J × CBA). Heterozygote
males were used so that every litter would also
contain wild type embryos, which could serve
as an internal negative control. Females were
checked daily for the presence of a vaginal
plug, and when a plug was detected, that day
was designated 0.5 day postcoitum (dpc).
Compounds and exposures. E2, EP, DES,
and BPA were all purchased from Sigma-
Aldrich (Roosendaal, The Netherlands). For
injections, compounds were dissolved in
corn oil (Sigma-Aldrich) at a concentration
of 10 mg/mL and then diluted in 1:10 steps
in corn oil to the required doses (DES,
10–1,000 µg/kg; EP, 10–10,000 µg/kg; BPA,
10–10,000 µg/kg). Compounds or vehicle
were injected intraperitoneally in 13.5 dpc
pregnant animals. Animal experiments were
performed with approval of the Netherlands
Academy of Arts and Sciences Animal Ethics
Committee. The IVIS imaging experiments
were done with additional approval of the
Animal Ethics Committee of NV Organon.
In vivo luciferase measurement. With the
Xenogen IVIS imaging system (Xenogen,
Alameda, CA, USA), luciferase activity was
monitored in living animals 0, 2, 4, 8, and
24 hr after compound injection. Animals were
injected subcutaneously with luciferin (150
µL, 30 mg/mL). After 15 min, the animals
were placed in a dark imaging chamber under
isoﬂurane anesthesia. Resulting photon emis-
sion from the luciferin/luciferase reaction was
detected with a CCD (charge-coupled device)
camera. The photon image obtained was
superimposed on a normal video image of the
mouse with Living Image software (Xenogen).
We used IGOR software (WaveMetrics
Corp., Lake Oswego, OR, USA) to quantify
the photon signal over the area encompassing
the embryos. For all pregnant animals, this
area was kept of equal size.
Luciferase measurement lysates. Embryos
were isolated either at 8 or 24 hr after 
compound injection and frozen at –80°C.
When embryos were isolated from the amni-
otic membranes, we kept tails separated and
stored at –20°C for subsequent DNA isolation
and polymerase chain reaction for presence of
the transgene, as described previously (Legler
et al. 2000). Only transgenic embryos were
used for further luciferase measurement.
Subsequently, embryos were thawed on ice
and lysis buffer [1% (vol/vol) Triton X-100,
2.5 × 10–2 M glycylglycine, 1.5 × 10–2 M
MgSO4, 4 × 10–3 M EGTA, and 1 × 10–3 M
dithiothreitol (DTT)] was added. Next, sam-
ples were sonicated, the lysate centrifuged, and
the supernatant collected. Samples (25 µL in
duplicate) were analyzed for luciferase enzyme
activity in a luminometer (LUMAC/3M BV,
Schaesberg, The Netherlands) with injection
of 100 µL luciferin substrate as previously
described (Lemmen et al. 2004). Luciferase
activity was corrected for protein content as
measured with the Bradford assay.
In vitro estrogenic activity assay in stable
cell lines. Stable 239HEK cell lines containing
human ER-α (hER-α) or hER-β and an estro-
gen-responsive reporter construct—similar to
the one introduced in the transgenic animals,
but without the ﬂanking insulator sequences—
were used and cultured as previously described
(Lemmen et al. 2002). Brieﬂy, cells were plated
in 96-well tissue culture plates (NUNC, Life
Technologies, Breda, The Netherlands) in
medium consisting of phenol red–free
Dulbecco’s modified Eagle’s medium/F12
(1:1) medium containing 3 × 10–8 M selenite,
10 µg/mL transferrin, 0.2% (wt/vol) bovine
serum albumin, and 5% (wt/vol) dextran-
coated charcoal-stripped fetal calf serum. After
24 hr, medium was refreshed and after another
24 hr, the medium was removed and fresh
medium containing test compounds (dissolved
in ethanol) was added. After 24 hr of incuba-
tion, the medium was removed and 50 µL lysis
solution [1% (vol/vol) Triton X-100, 2.5 ×
10–2 M glycylglycine, 1.5 × 10–2 M magne-
sium sulfate, 4 × 10–3 M EGTA, and 1 ×
10–3 M DTT] was added directly to the cells.
Luciferase activity of 25 µL cell lysate was mea-
sured with the Luclite Luciferase Reporter gene
assay kit (Perkin-Elmer, Brussels, Belgium)
according to the manufacturer’s instructions
using 25 µL Luclite solution on a Topcount
liquid scintillation counter (Perkin-Elmer).
Data analysis and statistics. We considered
one litter as a statistical unit rather than one
embryo because we assumed that all embryos
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Figure 1. In vivo activation of estrogen-responsive reporter construct by DES and EP in embryos. (A) In vivo activation of estrogen-responsive reporter construct
(luciferase) by DES and EP in 13.5 dpc transgenic embryos measured with IVIS; the number of photons produced by the reaction between luciferase and luciferin
is depicted in a color image superimposed on a video image of the pregnant animal. (B) Quantiﬁcation of the signal produced in the embryos after DES and EP
exposure. Values shown are mean ± SEM for oil (n = 5 litters), DES 10 µg/kg (n = 4), DES 100 µg/kg (n = 4), DES 1,000 µg/kg (n = 6), EP 10 µg/kg (n = 4), EP 100 µg/kg
(n = 2), EP 1,000 µg/kg (n = 5), and EP 10,000 µg/kg (n = 6). Abscissa, dose of DES/EP or oil; ordinate, photons/sec/cm2 measured in an area of the pregnant mouse
encompassing the embryos. 
*p < 0.05, #p < 0.001 compared with oil-exposed mean as determined by Kruskal-Wallis analysis followed by the Dunn’s posttest.in one litter were subject to the same variation
of the compound injection and placental trans-
fer. Therefore, the average ± SEM per litter was
calculated, and these were then averaged to
express the luciferase activity per group. All
data were log-transformed and tested for nor-
mality with the Shapiro-Wilks test using SPSS
12.0 (SPSS, Chicago, IL, USA). The data were
not normally distributed; therefore, we deter-
mined significant differences of treatment
groups from oil-exposed control using Kruskal-
Wallis analysis followed by the Dunn’s posttest
using GraphPad Prism 3.02 (GraphPad
Software Inc., San Diego, CA, USA). In addi-
tion, the presence of a linear trend in the dose
response was determined by analysis of vari-
ance followed by a posttest for linear trends
using GraphPad Prism 3.02. For the IVIS
time-course experiments, we performed a
Friedman test followed by Dunn’s posttest
using GraphPad Prism 3.02.
The in vitro dose–response activation
curves obtained with the stable cell lines
were fitted using the sigmoidal fit {y = a0 +
a1/1 + exp[–(x – a2)/a3]} in Slidewrite Plus
for Windows (version 3.0; BIS, Ridderkerk,
The Netherlands), which determines the ﬁt-
ting coefﬁcients by an iterative process mini-
mizing the c2 merit function (least squares
criterion). The EC50 (median effective con-
centration) values were calculated by deter-
mining the concentration by which 50% of
maximum activity was reached using the sig-
moidal ﬁt equation. The cell line data shown
are the average of at least two independent
experiments with each experimental point
performed in triplicate. Data are shown as a
percentage of maximal induction by E2.
Results
Estrogens activate endogenous ERs in trans-
genic embryos. To be able to measure luciferase
activity in the transgenic embryos with the
IVIS system, it was crucial that wild-type
mothers carry the transgenic embryos. If trans-
genic mothers had been used, strong photon
emission would have been generated after the
estrogen and luciferin injections, masking the
signal emitted from embryos. We chose
13.5–14.5 dpc as the time for exposure because
at this time point ERs are expressed in the
embryo (Lemmen et al. 1999) and because this
is a sensitive time point for disruption of repro-
ductive organs by prenatal estrogen exposure.
In nonexposed embryos, we detected no
luciferase activity with IVIS and barely any
luciferase activity in embryo lysates.
In utero luciferase activity in transgenic
embryos was induced dose dependently by
DES and EP. When measured 8 hr after expo-
sure, 100 and 1,000 µg/kg DES signiﬁcantly
induced luciferase activity when assessed with
the IVIS system (Figure 1) and in embryo
lysates ex vivo measured in the luminometer
(Figure 2). No plateau levels in luciferase activ-
ity were reached, and the proﬁle of induction
after DES exposure was similar for both meth-
ods used to assess luciferase activity. For EP
only, the 10,000 µg/kg dose was able to signiﬁ-
cantly induce luciferase activity when measured
with IVIS after 8 hr (Figure 1). When meas-
ured ex vivo in embryo lysates, 1,000 µg/kg EP
already signiﬁcantly induced luciferase activity
(Figure 2). Fold induction of luciferase activity
of estrogen exposed over controls 8 hr after
exposure was, however, lower using IVIS com-
pared with measurements in lysates. For DES
doses of 100 and 1,000 µg/kg, induction was
5-fold and 14-fold greater, respectively, when
measured with the IVIS system, whereas it was
41-fold and 51-fold greater, respectively, when
measured ex vivo on embryo lysates. However,
these differences in induction are likely based
on a difference in noise rather than in signal.
Also, for EP inductions were larger when meas-
ured ex vivo than when measured with IVIS
(data not shown).
An important advantage of using the IVIS
system is that the luciferase induction can be
followed in time in a single animal, making it a
very useful tool for obtaining information on
the kinetics of tissue distribution and gene acti-
vation by compounds. With the IVIS measure-
ments, we observed a difference between DES
and EP in the kinetics of inducing luciferase
activity (Figure 3). DES (1,000 µg/kg) signiﬁ-
cantly induced luciferase activity, exceeding
levels in oil-exposed animals 2 hr after expo-
sure, and this activity peaked 8 hr after expo-
sure (Figure 3). In contrast, only 8 hr after EP
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Figure 2. Ex vivo measurement of embryo lysates of in utero activated estrogen-responsive reporter con-
struct (luciferase) 8 and 24 hr after exposure to DES (A, B), EP (C, D), and BPA (E, F). Values shown are
mean ± SEM for the 24 hr measurements: oil (n = 9 litters) DES 10–1,000 µg/kg (n = 8–9), EP 10–100 µg/kg
(n = 5), EP 1,000–10,000 µg/kg (n = 7–8), BPA 10–100 µg/kg (n = 2), and BPA 1,000–10,000 µg/kg (n = 6–8);
and for the 8 hr measurements: oil (n = 3), DES 1 µg/kg (n = 2), DES 10 µg/kg (n = 5), DES 100 µg/kg (n = 8),
DES 1,000 µg/kg (n = 3), EP 100 µg/kg (n = 3), EP 1,000 µg/kg (n = 5), BPA 100 µg/kg (n = 2), BPA 1,000 µg/kg
(n = 8), and BPA 10,000 µg/kg (n = 5). Abscissa, dose of DES, EP, BPA, or oil; ordinate, Luc-units/mg protein
as measured on luminometer (LUMAC).
*p < 0.05, **p < 0.01, #p < 0.001 compared with oil-exposed mean as determined by Kruskal-Wallis analysis followed by the
Dunn’s posttest.exposure (10,000 µg/kg), luciferase activity was
signiﬁcantly above levels in oil-exposed animals,
with a peak at 24 hr after exposure (Figure 3).
This difference in kinetics thus complicates
comparing relative potencies of these estrogens
to induce luciferase activity. At 24 hr after
estrogen exposure, the embryos were isolated
and luciferase activity was measured ex vivo,
showing that 100 and 1,000 µg/kg DES and
1,000 and 10,000 µg/kg EP were able to sig-
niﬁcantly induce luciferase activity compared
with oil-exposed controls (Figure 2).
BPA activates ERs in transgenic embryos.
Eight hours after exposure to 10,000 µg/kg
BPA, luciferase activity was higher than in oil-
exposed animals when measured with IVIS
(Figure 4), although this was not statistically
significant. To be able to visualize the weak
BPA signal, the scale bar of the superimposed
video image had to be adjusted compared with
Figures 1 and 3. When lysates from embryos
sacriﬁced 24 hr after exposure were measured,
no difference between oil- and BPA-exposed
animals was found (Figure 2). Because BPA,
like DES, may enter the fetal circulation
rapidly (Miyakoda et al. 1999; Takahashi and
Oishi 2000), other embryos were isolated 8 hr
after exposure to 100 and 1,000 µg/kg BPA,
EP, and DES or oil. At this time point,
luciferase activity was signiﬁcantly higher after
exposure to 1,000 and 10,000 µg/kg BPA
compared with oil-exposed animals (Figure 2).
Therefore, at least at early time points, BPA is
able to transactivate the embryonic ERs and
resembles DES rather than EP in its kinetics
of luciferase activation.
In vitro potency of estrogens and BPA. The
compounds used for the exposure experiments
of transgenic animals were also tested in an
in vitro assay to separately assess their potency
to activate ER-α or ER-β using a similar
reporter gene as used in the transgenic animals,
only without the ﬂanking insulator sequences
(Figure 5). All three compounds activated
hER-α and hER-β in vitro. The EC50 values
for ER-α were 3.9 × 10–11 M, 8.5 × 10–12 M,
and 1.6 × 10–7 M for DES, EP, and BPA,
respectively. EC50 values for ER-β were 3.9 ×
10–11 M, 8.5 × 10–12 M, and 1.6 × 10–7 M for
DES, EP, and BPA, respectively. In these
experiments, BPA was found to be 5,000 times
less active than DES in activating ER-α and
1,400 times less active than DES toward ER-β
transactivation. EP was 4.6 times more potent
than DES in activating hER-α and just as
potent as DES in activating hER-β. These
results conﬁrm the reported weak estrogenicity
of BPA in vitro.
Discussion
We successfully applied our new sensitive
estrogen reporter mice to assess the ability of
DES, EP, and BPA to activate ER signaling in
embryos. In the present study, BPA exposure
of pregnant mice induced the estrogen reporter
through activation of endogenous ERs in
mouse embryos. Hence, the generated in vivo
model was successful in detecting estrogenic
activity of a suspected environmental estrogen
in embryos exposed in utero. In addition, our
results show that in utero activation of ERs by
BPA, at early time points after exposure,
requires much lower doses than extrapolations
from in vitro measurements would predict.
Because barely any luciferase activity
could be measured in nonexposed embryos,
we concluded that either there are no active
endogenous estrogens during the life stage
tested (13–14.5 dpc), or that our model is not
sufﬁciently sensitive to detect their presence.
Very low levels of estrogens have been
described to be present in steroid extracts of
mouse embryo homogenates as determined in
estrogenic activity measurements (Lemmen
et al. 2002). These levels may, however, be
too low to activate endogenous ERs or are not
able to activate ERs in vivo because of such
different factors as tissue distribution and inac-
tivation through binding proteins. It is possi-
ble that measurements of luciferase activity on
dissected organs from embryos would prevent
dilution of the luciferase signal below the
detection limit. The low sensitivity of our
model is also apparent in the high doses of
DES and EP needed to be able to show a sig-
niﬁcant luciferase induction (Figures 1 and 2).
From measurements taken after mice
pregnant with transgenic embryos were
exposed to DES and EP, it was possible to
evaluate the ability of the in vivo model to
detect well-known estrogens in embryos
exposed in utero. Exposure to DES showed a
dose- and time-dependent induction of
luciferase activity. The kinetic data obtained
with the IVIS system showed that for all DES
doses peak activity occurred at 8 hr after
exposure. Previous studies using 14C-DES
have shown that upon injection of pregnant
mice, fetal plasma levels reach a peak after 2 hr
and then disappear slowly (McLachlan 1977).
The time difference in induction of maximal
luciferase activity (i.e., after 8 hr) compared
with an expected earlier DES peak in fetal
plasma (i.e., after 2 hr) may be additionally
due to the time required for transcription and
translation of luciferase. Comparing DES with
EP, it is evident that EP also shows a dose-
dependent increase in luciferase activity.
However, the EP-induced peak of luciferase
activity was not seen before 24 hr after expo-
sure. The observed time course of EP-induced
luciferase activation could be due to a slow
transfer to the embryos of EP itself or a rela-
tively slow uptake by target tissues. Because no
data are available on the kinetics of placental
transfer of EP, only data on placental transfer
of E2 can be used for comparison. In rhesus
monkeys, placental transfer of 14C-DES and
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Figure 3. In utero time course of activation of estrogen-responsive reporter construct by DES and EP in
embryos. (A) In utero time course of activation of estrogen-responsive reporter construct (luciferase) by
DES and EP in transgenic embryos measured with IVIS. The number of photons is depicted in a color
image superimposed on a video image of the pregnant animal. (B) Quantiﬁcation of the signal produced in
embryos after DES and EP exposure. Values shown are mean ± SEM for oil (n = 5 litters), DES 10 µg/kg
(n = 4), DES 100 µg/kg (n = 4), DES 1,000 µg/kg (n = 6), EP 10 µg/kg (n = 4), EP 100 µg/kg (n = 2), EP 1,000 µg/kg
(n = 5), and EP 10,000 µg/kg (n = 6). The 10,000 µg/kg dose was not tested for DES. Abscissa, time in hours
after hormone exposure; ordinate, photons/sec/cm2 measured in an area of the pregnant mouse encom-
passing the embryos.
*p < 0.05, **p < 0.01, #p < 0.001 compared with oil-exposed mean as determined by Kruskal-Wallis analysis followed by the
Dunn’s posttest.14C-E2 was similar (Hill et al. 1980). Similar to
embryos, exposure of adult transgenic animals
to EP induced peak activation of luciferase at
24 hr after exposure (Lemmen et al. 2004),
suggesting that a difference in placental transfer
is unlikely to explain the delay in activation of
luciferase by EP compared with DES. Another
explanation for the difference observed
between EP and DES exposure in peak
luciferase activity could be that EP is initially
bound to binding proteins in the serum and
uptake by the embryonal target tissues is there-
fore slower compared with DES, which has
much lower affinity to binding proteins
(Arnold et al. 1996; Simmons et al. 1994).
However, when E2 was tested in adult animals
(Lemmen et al. 2004), it did show a peak in
luciferase activity at 8 hr rather than at 24 hr;
because E2 is bound to binding proteins as is
EP, this suggests that the time needed for
removal of the propionate groups could
explain the difference in kinetics between EP
and DES.
In pregnant rats, BPA has been shown to
enter the fetal circulation with a peak concen-
tration after 15–20 min (Takahashi and Oishi
2000). When exposing pregnant mice to
100 mg/kg BPA given subcutaneously, BPA
was detected 30 min after exposure in fetal sera,
liver, brain uterus, and testes (Domoradzki
et al. 2003; Shin et al. 2002; Uchida et al.
2002). In the present study, BPA was found to
signiﬁcantly induce luciferase activity at doses
of 1,000 and 10,000 µg/kg 8 hr after exposure.
The kinetics of luciferase induction by BPA,
measured with the IVIS system, resemble the
proﬁle of DES. Although the molecular struc-
ture of BPA and DES is similar, it remains
unknown whether this contributes to the simi-
larity in their kinetics in inducing luciferase
activity. Testing more estrogenic compounds
with various structures could shed light on this
question.
Like DES, BPA showed a transient induc-
tion of luciferase activity in embryos; thus,
estrogenic potency of BPA is compared with
DES rather than with EP. In utero luciferase
activation by BPA in transgenic embryos at
8 hr after exposure was significant from oil-
exposed controls with 1 mg/kg BPA. Likewise,
Nagel et al. (2001) found a signiﬁcant increase
in ER transcriptional activity in the adult
uterus after exposure to 1 mg/kg BPA, whereas
this dose did not induce a uterine wet weight
response. DES was signiﬁcantly different from
oil-exposed controls at a dose of 100 µg/kg
(only 10 times less than BPA), which suggests a
high in vivo estrogenic potency of BPA. It
should be noted that doses of 1 and 10 µg/kg
DES induce almost a similar transcriptional
activation (Figure 2), and the activation is
approximately 20% of maximal activity
induced by DES. In vitro, BPA was three to
four orders of magnitude less active than DES,
consistent with previous reports (Andersen
et al. 1999; Kim et al. 2001; Kuiper et al.
1998). Thus, in our hands the relative potency
of BPA seems to be higher in utero than in vitro
on ER-α, which is the most abundantly
expressed ER during embryogenesis (Lemmen
et al. 1999). We believe this difference is not
due to the use of human ERs in vitro versus the
endogenous mouse ERs in utero. It has been
shown that human and mouse ER-α have the
same affinity for DES and BPA (Matthews
et al. 2000), and this is likely to be the case for
ER-β as well. One explanation for a higher
estrogenic potency of BPA in utero versus
in vitro could be that in vivo BPA is converted
to metabolites with enhanced estrogenicity
(Ben-Jonathan and Steinmetz 1998; Yoshihara
et al. 2004), although others have shown that
BPA is mainly metabolized to a less active
metabolite BPA monoglucuronide
(Domoradzki et al. 2003; Pottenger et al.
2000). Another explanation could be that BPA
has a lower afﬁnity for the steroid-binding pro-
teins present in serum, giving it a higher
bioavailability than EP, a factor that is not
taken into account in the in vitro assay.
However, we feel this cannot explain the in vivo
versus in vitro potency difference as we compare
BPA with DES, and DES does not have a high
afﬁnity for binding proteins.
Strain differences in sensitivity to estrogens
have been reported. The strain used in this
study, C57Bl/6J (B6), has been shown to be
more sensitive than CD-1 mice with respect to
reduction of testis weight after estrogen expo-
sure (Spearow et al. 1999). Also, for other end
points of estrogen exposure, the B6 strain has
been shown to be a sensitive strain (Roper
et al. 1999; Spearow et al. 2001). In CFLP
mice, 0.5 mg/mouse (~ 16.7 mg/kg) BPA was
reported to be inactive in the uterine wet
weight assay, whereas the other dose tested
(5 mg/mouse, ~ 167 mg/kg) was toxic
(Coldham et al. 1997). In CD-1 mice, a
uterotrophic response was induced by
100 mg/kg BPA (Markey et al. 2001), whereas
in B6C3F1 mice, doses between 0.8 and
8 mg/kg could induce uterine wet weight
increase (Papaconstantinou et al. 2000). In the
present study, a significant induction of
luciferase activity in utero was detected after
Article | Lemmen et al.
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Figure 4. In utero time course of activation of estrogen-responsive reporter construct by BPA in embryos.
(A) In utero time course of activation of estrogen-responsive reporter construct (luciferase) by
10,000 µg/kg BPA in transgenic embryos measured with IVIS. The number of photons is depicted in a color
image superimposed on a video image of the pregnant animal. (B) Quantiﬁcation of the signal produced in
embryos after BPA exposure. Values shown are mean ± SEM (n = 5). Abscissa, time in hours after hor-
mone exposure; ordinate, photons/sec/cm2 measured in an area of the pregnant mouse encompassing the
embryos. Note that the scale differs from those in Figures 1 and 3.
Figure 5. Transactivation of hER-α and hER-β by DES (A), EP (B), and BPA (C) presented as a percentage of maximal induction by E2. Values shown are mean ± SEM
of three independent experiments done in triplicate. Abscissa, log molar concentration of hormone; ordinate, transcriptional activity as percentage of maximal
induction by E2 for each ER subtype.
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administration of 1 mg/kg BPA to pregnant
females. The use of nontransgenic mother ani-
mals with a pure B6 background rather than
the B6/CBA cross used could further increase
the sensitivity of the present model.
In conclusion, we have shown that the
mouse model presented here can be used to
detect activation of ERs by maternally applied
BPA and that other estrogens can be detected
in living embryos in utero. BPA was more
potent than would be estimated from in vitro
assays, although its intrinsic activity is still
lower than that of DES and EP. On the other
hand, effects on individual embryonic organs
might be larger and could be underestimated
because we measured total embryo lysates.
When considering that nanomolar levels of
BPA have been measured in human serum
(Takeuchi and Tsutsumi 2002), human
amniotic fluid at 15–18 weeks of gestation
(Ikezuki et al. 2002), and surface water
(Fromme et al. 2003), concern about BPA
exposure during embryonic/fetal life seems to
be justiﬁed. It should be noted, however, that
in our model the BPA effect had a more tran-
sient nature than did that of the other hor-
mones. If and how this will translate to a
biological effect in the exposed embryos
should be the target of further investigations
using other approaches.
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